"We look forward to working with the talented team at GenoLogics and to further integrate their life science software as part of the overall
The completion of the acquisition demonstrates Illumina’s commitment to drive the adoption of sequencing in new markets and improve the genomic workflow. GenoLogics’ Clarity LIMS™ software enables lab efficiencies and improved sample throughput with increased accuracy, fast turnaround, sample traceability, and preconfigured instrument integrations.
View source version on businesswire.com: http://www.businesswire.com/news/home/20150901005460/en/
Source:
Illumina, Inc.
Investors:
Rebecca Chambers, 858-255-5243
rchambers@illumina.com
or
Media:
Eric Endicott, 858-882-6822
pr@illumina.com